Shots: Recently, PolTREG announced positive long-term follow-up data for PTG-007 from the P-I/II studies for early-onset type 1 diabetes PolTREG develops therapies using T-regulatory cells for autoimmune diseases. With the positive results, PolTREG has met EMA’s requirement to confirm the safety of Treg therapies at least five years after the administration Today, at PharmaShots, we…
